Navigation Links
Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Multiple Myeloma at AACR Annual Meeting
Date:4/15/2008

CALGARY, April 15 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced that an oral presentation by Dr. Chandini Thirukkumaran of the Tom Baker Cancer Centre, Calgary, entitled "Targeting Multiple Myeloma with Oncolytic Viral Therapy" was presented today at the American Association for Cancer Research (AACR) Annual Meeting. The meeting is being held in San Diego, California from April 12-16, 2008.

The presentation covered preclinical work using reovirus as a purging agent during autologous (harvested from the patient themselves) hematopoietic stem cell transplants for multiple myeloma. The results demonstrated that up to 70% of multiple myeloma cell lines tested showed reovirus sensitivity and reovirus induced cell death mediated through apoptosis.

The investigators concluded that this preclinical data supports initiating a Phase I purging trial using reovirus against multiple myeloma.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at this meeting with respect to REOLYSIN(R), the Company's expectations related to the results of trials investigating delivery of REOLYSIN(R), and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainti
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2015)... ... ... For many years, metal-on-quartz filters were the industry standard for the calibration of ... 4000-7000, a Perkin Elmer 800-1100 or a Shimadzu 3600-3700, these filters would work like ... SRM-2031 series going back for many years. Unfortunately, these standards remained unusable for the ...
(Date:7/3/2015)... ... ... The global failure analysis market is expected to reach $7,147.0 million by 2020, ... to grow at the highest CAGR of 8.46%; its growth is expected to be ... academic institutions for root cause analysis of failure. The market based on the geographic ...
(Date:7/3/2015)... 2015 Forskere kan ... på  http://www.openinnovationinscience.at om efteruddannelsesprogrammet "Lab for ... i Wien .  ... forskere og videnskabsmænd foretaget af Ludwig Boltzmann ... for sundhedsvidenskaben manglen på incitamenter til at ...
(Date:7/2/2015)... Scotland , July 2, 2015 ... Bio-tech procurement company Amici Procurement has chosen ... to help it move to Office 365. ... provides small to medium-sized companies in the bio-tech ... all aspects of the purchasing cycle to help them ...
Breaking Biology Technology:FireflySci Simplifies the Calibration of UV Spectrophotometers with FUV Photometric Accuracy Standards 2FireflySci Simplifies the Calibration of UV Spectrophotometers with FUV Photometric Accuracy Standards 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3Biotech Procurement Company Moves to Office 365 with iomart 2
... , PHOENIX and SAN CARLOS, Calif., Oct. 10 ... data today from its Phase 2 clinical trial of ... (AAPM) 20th Annual Clinical Meeting in Phoenix, Arizona. ... stage investigational product candidate in clinical development for the ...
... developing new sensors to detect chemical agents and illegal drugs ... terrorist attacks. The devices will use special gel pads ... sample which is then analysed by a scanning instrument that ... allow better, faster decisions to be made in response to ...
... N.C. The natural cycle of building bone to maintain ... calcium needs is delicately balanced, but diseases like osteoporosis break ... bone fractures. The results from a new study ... be able to fight osteoporosis and other degenerative bone diseases. ...
Cached Biology Technology:Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix 2Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix 3Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix 4New technology detects chemical weapons in seconds 2New approach for growing bone comes from Duke preclinical research 2
(Date:6/18/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market announces that its Wocket® smart wallet will be ... Mark", scheduled to air on WABC Radio (am770) in ... The broadcast air- time for the extensive ... NXT-ID, Inc.,s CEO Gino Pereira will be discussing ...
(Date:6/17/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that Xiaomi, one of the world,s largest mobile ... ® family of capacitive touchscreen solutions and ... for its latest smartphones, the Xiaomi Mi Note ... in-cell display solutions and DDICs in discrete display ...
(Date:6/16/2015)... June 16, 2015  With the increasing number and ... a top concern. The recent compromise of Federal ... for strong authentication within government agencies. HYPR ... one-time password (OTP) authenticator, has been submitted for testing ... Level 3 validation for tamper proofing. ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... populating the growing brain, neural stem cells must strike a ... the cells multiply to provide plenty of starting materials ... If the stem cells proliferate too much, they could ... proliferate too little, there may not be enough cells to ...
... / b3c newswire / - KINAXO Biotechnologies GmbH ... service portfolio. KinAffinity provides invaluable information about a ... of interest. It simultaneously determines affinities for native ... overcomes the limitations of traditional biochemical assays that ...
... of researchers from the University of Maryland Center for ... study to forecast the effects of environmental change on ... by a $620,000 grant from the National Science Foundation, ... Preserve near Alexandria, Virginia. "Freshwater marshes are integral ...
Cached Biology News:UNC study pinpoints gene controlling number of brain cells 2KINAXO launches KinAffinity services for efficient profiling of kinase inhibitors in cells or tissue 2